Elanco Animal Health Incorporated · ELAN · FY2026 Q3 · Calendar Q4 2026
Elanco lifts 2026 outlook as innovation products drive Q3 growth
The supplied Q3 analysis supports a growth thesis centered on differentiated pet-health products, farm-animal demand and productivity initiatives. The higher full-year outlook and margin expansion strengthen that case, while competition, regional farm-animal cycles and the Costco non-renewal remain meaningful execution risks.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about ELAN FY2026 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with Q2's raised outlook for 6–7% full-year organic growth, management raised the full-year organic revenue growth outlook to about 8% in Q3. The supplied analysis also reports 11% year-over-year revenue growth, 9% organic growth and 300 basis points of gross-margin expansion.
Guidance delta
Raised full-year outlook: about 8% organic revenue growth, adjusted EBITDA growth of 17% at the midpoint and adjusted EPS of $1.17–$1.20. The prior quarter's organic revenue growth outlook was 6–7%.
Key takeaways
- Q3 revenue grew 11% year over year, including 9% organic growth, according to the transcript analysis.
- Gross margin expanded 300 basis points; innovation revenue reached $328 million.
- Management raised full-year outlook, citing product innovation, pricing and volume growth.
- Net leverage improved to 2.9x, while the analysis highlights free-cash-flow generation and debt reduction.
- Costco's non-renewal is expected to affect Q1 2027; new retail partners were cited as an offset.
Management priorities
- Scale the Big 6 innovation portfolio, with a stated goal to double its revenue by 2028.
- Prepare Befrena's national launch and Credelio Quattro's European launch for Q1 2027.
- Continue Elanco Ascend productivity initiatives, targeting $200–$250 million of EBITDA savings by 2030.
Follow ELAN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationElanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MRNA Moderna, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.3% | Moderna raises 2026 outlook as vaccines and oncology advance |
| MTD Mettler-Toledo International Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.6% | +4.8% | Mettler-Toledo raises growth outlook after Q3 strength led by China |
| GMAB Genmab A/S | FY2026 Q3 · Calendar Q4 2026 | +55.6% | -4.3% | Genmab pairs nine-month growth with a heavier launch agenda |
| NTRA Natera, Inc. | FY2026 Q3 · Calendar Q4 2026 | -49.3% | -15.2% | Natera raises 2026 revenue outlook as Signatera drives Q3 growth |
| STE STERIS plc | FY2027 Q2 · Calendar Q4 2026 | +9.7% | +2.5% | STERIS raises FY2027 EPS outlook after 9% revenue growth |
| BDX Becton, Dickinson and Company | FY2026 Q4 · Calendar Q4 2026 | +2.0% | +2.1% | BD FY2026: Broad Growth, With FY2027 Margin and Alaris Risks |
Latest beats and misses
Who reports nextBeat on EPS
- FNFFY2026 Q3 · November 5, 20260.0% EPS+6.6% move
- MTDFY2026 Q3 · November 5, 2026+3.6% EPS+4.8% move
- IAGFY2026 Q3 · November 5, 2026+16.7% EPS+4.6% move
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
- STEFY2027 Q2 · November 4, 2026+9.7% EPS+2.5% move
- IRMFY2026 Q3 · November 5, 2026+4.6% EPS-11.1% move
Missed on EPS
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
- UHALFY2027 Q2 · November 4, 2026-15.4% EPS-3.2% move
- LAMRFY2026 Q3 · November 5, 2026-3.6% EPS-0.8% move
- CMIFY2026 Q3 · November 5, 2026-6.0% EPS-4.9% move
Get the ELAN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-06T17:09:19.540957+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T17:20:43.557169+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T17:20:43.554378+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.